Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05925374
Other study ID # R34DA053758
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2023
Est. completion date June 7, 2023

Study information

Verified date June 2023
Source Wayne State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a community-engaged research project that aims to identify and pilot test interventions that may reduce substance use stigma among professionals at primary care sites serving patients who might be exposed to HIV or are living with HIV. Our goal is to develop a multi-level substance use stigma intervention that leverages 1) education and 2) organizational policy to address structural drivers of stigma and the stigmatizing professional attitudes and behaviors that affect patients. Hypothesis: the results of the trial pilot research and are expected to provide scientific evidence demonstrating feasible and potentially effective substance use stigma reduction interventions that go beyond simple individual-level professional training. We plan to build on the data from this pilot trial study to then further test the multi-level intervention in another larger trial study with primary care organizations to determine whether the intervention addresses multiple complex drivers of substance use stigma that influence HIV prevention and care outcomes among people who use drugs.


Description:

This planning project aims to develop and pilot test elements of a multi-level substance use stigma reduction intervention. This study builds on past research indicating educational interventions can meaningfully reduce provider stigma related to substance use by examining the extent to which educational interventions may be enhanced by organizational policies addressing structural drivers of stigma toward people who use drugs operating in the health sector. The ultimate goal of this pilot study is to identify feasible and potentially effective substance use stigma reduction interventions that go beyond simple individual-level professional training and that could be tested in a larger subsequent trial study. This project will use a community-engaged approach with federally-qualified health centers (FQHCs) and other primary care sites to generate pilot data and establish protocols that not only measure self-reported changes in attitudes among health professionals but also use patient surveys and electronic medical records to measure the effect of educational and policy interventions on changes to clinical practice and patient outcomes. Initial planning will focus on developing and pilot testing an educational curriculum (Aim 1) that addresses key drivers of provider-based stigma and FQHC facility recruitment and participation in policy development to address structural stigma (Aim 2). The latter half of the planning process will focus on refining and finalizing the trial design, survey instruments, data collection and management procedures, and drafting the trial protocol (Aim 3). For Aim 1, the project team will design a curriculum addressing stigma related to substance use among the primary care workforce. The study team will prepare a 2-hour interactive curriculum to be used in an education session for individuals in any professional role (providers, other clinical support staff, and receptionists). The lead PI, Dr. Madden, will co-teach the course with a community consultant who has firsthand experience with SUD and harm reduction work. Including a co-teacher with such firsthand experience provides a contact-based approach to reducing stigma, which has been shown to reduce stigmatizing professional attitudes in several past studies. The curriculum will be piloted with ~35 primary care professionals, including physicians, other clinical support staff, and reception staff to assess changes to attitudes and intended behaviors that are indicative of substance use stigma. These changes will be assessed using validated surveys of provider-based stigma and new survey measures using the Theory of Planned Behavior to assess factors influencing professional behavior. A focus group with 6-10 pilot participants will be used to obtain qualitative feedback on the curriculum in order to refine and revise the training for the subsequent trial. The focus group will follow a Qualitative Description Approach, a methodology used in health services research to explore perspectives and experiences among people directly involved in a health/social phenomenon. For Aim 2, FQHCs and other primary care sites providing HIV prevention and care services will be identified and approached in year 1 by the PIs. PIs will meet with interested FQHC administrators to explain the trial planning project and those administrators who agree to participate in trial planning will be asked to allow administrators and personnel to volunteer for qualitative interviews regarding facility policies and practices affecting stigma and HIV prevention and care for people who use drugs. In-depth semi-structured interviews with 15-20 FQHC professionals will be conducted in order to identify a suitable stigma policy to test in a larger subsequent trial study. Interviews will also be guided by the Qualitative Description Approach. Analyses will occur simultaneously with data collection and use thematic analysis. A policy proposal based on the qualitative analysis will be provided to FQHCs, and revised based on their feedback. For Aim 3, the study team will collaborate with designated representatives ("champions") from each primary care site to design and finalize a trial protocol that tests a multi-level stigma intervention combining professional education and policy changes aimed at stigma reduction. The study team will work with the site champions in quarterly or monthly meetings (depending on scheduling availability of the champions) to review results from the training surveys, focus groups, and policy interviews, and to assure protocol feasibility and that site feedback is integrated into the pilot study and the ultimate goal of planning a larger subsequent trial study plans. A draft of the trial protocol will be provided to FQHC personnel along with anonymous online surveys soliciting feedback. The feedback will be analyzed by the project team and the organizational project champions, and the protocol will be revised. The initial plan for the larger trial study that this pilot trial will inform includes a cluster randomized trial with 8 primary care sites and 80 primary care providers. Primary care providers will be the primary sampling units (i.e., the clusters), and patients will be the secondary sampling units. Randomization will first happen at the FQHC level so that all providers at a facility receive the same intervention in one of four arms: 1) facilities where personnel receive an educational intervention addressing provider-based stigma and facilities implement policy change aimed at reducing structural stigma toward PWUD; 2) facilities where personnel receive an educational intervention, but do not alter policies; 3) facilities that implement policy change, but personnel do not receive an educational intervention; and 4) control facilities without intervention implementation. For 20 random providers, 20 patients with substance use disorders (~400 patients total) will be selected in a second stage of randomization for survey participation. Patient surveys will include validated measures of anticipated, received, and internalized stigma, as well as validated tools to assess treatment adherence and use of harm reduction and substance use treatment services. Aggregated de-identified electronic medical records data from all patients of all participating providers will also be assessed as secondary sampling units. These patient outcomes for each primary care provider will be assessed to determine the effect of the multi-level stigma intervention. Electronic medical records and survey data will be collected for all arms at baseline and every 6 months for 24 months. Other clinical staff (e.g., nurses) and reception staff who interact with patients will be included in educational interventions, and may too be affected by policy changes (to be determined by outcomes of Aim 2), but will not be a primary sampling unit. The trial will require a separate IRB approval, and the current IRB approval is only for the pilot trial and planning activities in the R34.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date June 7, 2023
Est. primary completion date May 17, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Employed at a federally qualified health center (FQHC) or other primary care site - For training and focus group participants (primary outcomes), volunteer is involved in direct interaction with patients - For interview and trial feasibility survey participants (secondary outcomes), volunteer is a decision-maker at the FQHC and/or directly interacts with patients Exclusion Criteria: - Not formally employed at a primary care facility (e.g., volunteer position at the site)

Study Design


Intervention

Behavioral:
Substance use stigma training
The intervention is an interactive professional educational training that is designed to manipulate behavioral and normative beliefs in order to address bias and alter professional practices towards patients who use drugs.

Locations

Country Name City State
United States Wayne State University Detroit Michigan

Sponsors (2)

Lead Sponsor Collaborator
Wayne State University Loyola University Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Provider-based stigma (SDS measure) As reported in surveys taken by primary care professionals using the social distance scale (SDS) Change from baseline SDS score (measured 0-7 days prior to training) at 0-7 days post-training (pre/post design)
Primary Provider-based stigma (MCRS measure) As reported in surveys taken by primary care professionals using the medical condition regard scale (MCRS) Change from baseline MCRS score (measured 0-7 days prior to training) at 0-7 days post-training (pre/post design)
Primary Provider-based stigma (planned behavior measure) As reported in surveys taken by primary care professionals using answers to questions about planned stigmatizing actions based on the Theory of Planned Behavior Change from baseline planned behavior score (measured 0-7 days prior to training) at 0-7 days post-training (pre/post design)
Primary Stigma training feasibility Qualitatively assessed in focus groups up to 5 months after the training
Secondary Stigma policy feasibility Qualitatively assessed in in-depth interviews with primary care personnel One-time interview lasting 45-60 minutes per participant
Secondary Qualitative assessment of feasibility of the multi-level stigma intervention trial plan Assessment of the feasibility of the plan to test the multi-level (education targeting individual-level and organizational policy targeting structural-level) substance use stigma intervention at the participating primary care sites will be qualitatively assessed through open-ended survey questions. Surveys will be distributed to staff (administrators, providers, nursing staff, reception staff) at all primary care sites participating in the pilot research. One-time survey lasting ~15 minutes per participant
Secondary Quantitative assessment of feasibility of the multi-level stigma intervention trial plan (FIM measure) Quantitative assessment of the plan to test the multi-level (education targeting individual-level and organizational policy targeting structural-level) substance use stigma intervention at the participating primary care sites will be quantitatively assessed through the Feasibility of Intervention Measure (FIM). Surveys will be distributed to staff (administrators, providers, nursing staff, reception staff) at all primary care sites participating in the pilot research. One-time survey lasting ~15 minutes per participant
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2